Press release



IBA TO PRESENT AT THE JEFFERIES 2016 HEALTHCARE CONFERENCE

Louvain-La-Neuve, Belgium, 6 June 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that Jean-Marc Bothy, Chief Strategy Officer, will present at the Jefferies 2016 Healthcare Conference in New York. The presentation will take place on Tuesday, June 7, 2016 at 4:30 pm EDT.

A live webcast of the presentation will be accessible by visiting the Investors section of IBA's website at www.iba-worldwide.com. A replay of the webcast will be archived on the Company's website following the presentation.

Ends

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,300 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA Jean-Marc Bothy Chief Strategy Officer +32 10 475 890 Investorrelations@iba-group.com

Thomas Ralet Vice-President Corporate Communication +32 10 475 890 Communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications Amber Fennell, Matthew Neal, Ivar Milligan +44 (0) 20 3709 5700 IBA@consilium-comms.com

Rx Communications Group (US) Melody Carey +1 917 322 2571 mcarey@RxIR.com

Press release | 6 June 2016